摘要
目的 探讨曲妥珠单抗联合化疗对HER-2阳性胃癌患者T淋巴细胞亚群及血清肿瘤标志物水平的影响。方法 收集我院2019年1月至2020年12月收治的HER-2阳性晚期胃癌患者分为对照组(n=49)和治疗组(n=49)。对照组接受SOX方案,治疗组接受SOX方案联合曲妥珠单抗。治疗2个周期后评价疗效作为主要研究终点。次要终点为Karnofsky(KPS)功能状态评分、1年生存率、毒副反应发生率,采用Semi-Bio特异性细胞检测法检测CD3^(+)、CD4^(+)、CD8^(+)细胞含量,并计算CD4^(+)/CD8^(+),电化学发光免疫法检测血清肿瘤标志物,包括糖类抗原(CA724)、糖类抗原199(CA199)及癌胚抗原(CEA)。结果 2个周期后,治疗组疾病控制率为91.8%,显著高于对照组65.3%(P<0.05)。治疗后两组患者血清中CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)比值及KPS评分均显著高于治疗前,血清CA199、CEA、CA724水平显著低于治疗前(P<0.05);治疗组CD8^(+)低于治疗前(P<0.05);治疗后治疗组血清CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)比值及KPS评分均显著高于对照组,血清CEA水平显著低于对照组(P<0.05)。对照组和治疗组1年生存率分别为46.94%(23/49)和79.59%(39/49),差异具有统计学意义(P<0.001)。结论 曲妥珠单抗联合化疗可改善HER-2阳性胃癌患者免疫功能,抑制肿瘤标志物水平。
Objective To investigate the effects of trastuzumab combined with chemotherapy on T lymphocyte subsets and serum tumor markers in patients with HER-2 positive gastric cancer. Methods Patients with HER-2 positive advanced gastric cancer admitted to our hospital from January 2019 to December 2020 were divided into control group(n=49) and treatment group(n=49). The control group received SOX regimen and the treatment group received SOX regimen combined with trastuzumab. Efficacy was evaluated after 2 cycles of treatment as the primary study endpoint. Secondary endpoints were Karnofsky(KPS) functional status score, 1-year overall survival rate, and incidence of toxicity and side effects. The contents of CD3^(+), CD4^(+), and CD8^(+)cells were detected by Semi-Bio specific cytoassay, and CD4^(+)/CD8^(+)was calculated. Serum tumor markers were detected by electrochemical luminescence immunoassay, including carbohydrate antigen(CA724), carbohydrate antigen 199(CA199) and carcinoembryonic antigen(CEA). Results After 2 cycles, the disease control rate in the treatment group was 91.8%, significantly higher than 65.3% in the control group(P<0.05). After treatment, the serum ratios of CD3^(+), CD4^(+), CD4^(+)/CD8^(+)and KPS score in 2 groups were significantly higher than before treatment, while the serum levels of CA199, CEA and CA724 were significantly lower than before treatment(P<0.05). CD8^(+)in treatment group was lower than that before treatment(P<0.05);After treatment, the ratio of CD3^(+), CD4^(+), CD4^(+)/CD8^(+)and KPS score in the treatment group were significantly higher than those in the control group, and the serum CEA level was significantly lower than that in the control group(P<0.05). The 1-year survival rates of the control group and the treatment group were 46.94%(23/49) and 79.59%(39/49), respectively, and the difference was statistically significant(P<0.001). Conclusion Trastuzumab combined with chemotherapy can improve the immune function, inhibit the level of tumor markers and reduce the incidence of
作者
朱麒
肖瑶
金丽艳
王月
ZHU Qi;XIAO Yao;JIN Liyan;WANG Yue(Department of Oncology,Wujin Hospital Affiliated to Jiangsu University(Wujin Clinical College,Xuzhou Medical University),Changzhou 213162,China)
出处
《临床肿瘤学杂志》
CAS
2023年第2期159-163,共5页
Chinese Clinical Oncology
基金
徐州医科大学2020年度江苏省重点实验室开放课题资助项目(XZSYSKF2020005)
常州市武进区科技支撑计划项目(WS201924)。
